Literature DB >> 26751606

Treatment of severe refractory epistaxis in hereditary hemorrhagic telangiectasia using a two-flap nasal closure method.

Benjamin H Timmins1, Benjamin N Hunter1, Kevin F Wilson2, P Daniel Ward2,3.   

Abstract

BACKGROUND: Nasal closure has been shown to effectively manage severe epistaxis refractory to other treatments in patients with hereditary hemorrhagic telangiectasia (HHT). The nasal closure procedure may be underutilized because of its surgical complexity and flap breakdown.
METHODS: This work is a retrospective review of 13 HHT patients treated for severe epistaxis with nasal closure between 2005 and 2013. Operating room (OR) time, need for revision surgery, preprocedure, and postprocedure epistaxis severity score (ESS), complete blood count values, and Glasgow Benefit Inventory (GBI) questionnaire results were collected for each patient. The technique is described. We characterize a typical nasal closure patient and compare outcomes based on our experience with the traditional 3-flap closure and a simplified 2-flap nasal closure procedure.
RESULTS: The average candidate for nasal closure in this series had an ESS of 7.88, hemoglobin (Hgb) of 8.3 g/dL, and received multiple transfusions, iron therapy, and cautery/coagulation procedures. Average ESS subsequent to nasal closure using the 2-flap method is 0.92 and mean GBI score is 56.3. Comparison of 5 patients who underwent the traditional 3-flap nasal closure procedure and 8 patients receiving the 2-flap nasal closure showed no significant difference in postoperative ESS or GBI metrics. Mean operating room times of the traditional and simplified methods were 3.12 hours and 1.44 hours (p = 0.0001). Mean time to first revision for 8 nasal closure patients was 21.5 months.
CONCLUSION: In short-term follow-up, the 2-flap procedure showed comparable effectiveness with significantly reduced complexity and operative time compared to the traditional nasal closure method.
© 2016 ARS-AAOA, LLC.

Entities:  

Keywords:  anemia; arteriovenous malformations; operative time; patient satisfaction; quality of life; reoperation; telangiectasia, hereditary hemorrhagic

Mesh:

Year:  2016        PMID: 26751606      PMCID: PMC4856581          DOI: 10.1002/alr.21703

Source DB:  PubMed          Journal:  Int Forum Allergy Rhinol        ISSN: 2042-6976            Impact factor:   3.858


  19 in total

1.  Treatment of hereditary hemorrhagic telangiectasia with submucosal and topical bevacizumab therapy.

Authors:  Tom T Karnezis; Terence M Davidson
Journal:  Laryngoscope       Date:  2011-12-06       Impact factor: 3.325

2.  Young's procedure in the treatment of epistaxis.

Authors:  D S Brooker; M J Cinnamond
Journal:  J Laryngol Otol       Date:  1991-10       Impact factor: 1.469

3.  Efficacy of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis.

Authors:  Tom T Karnezis; Terence M Davidson
Journal:  Laryngoscope       Date:  2010-12-16       Impact factor: 3.325

4.  Efficiency of laser treatment in patients with hereditary hemorrhagic telangiectasia.

Authors:  Gita Jørgensen; Bibi Lange; Jens Højberg Wanscher; Anette Drøhse Kjeldsen
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-06-26       Impact factor: 2.503

5.  Modified Young's procedure for refractory epistaxis due to hereditary hemorrhagic telangiectasia.

Authors:  J L Gluckman; L G Portugal
Journal:  Laryngoscope       Date:  1994-09       Impact factor: 3.325

6.  Closure of the nostrils in atrophic rhinitis.

Authors:  A Young
Journal:  J Laryngol Otol       Date:  1967-05       Impact factor: 1.469

7.  The Young's procedure for severe epistaxis from hereditary hemorrhagic telangiectasia.

Authors:  Sara L Richer; Urban W Geisthoff; Nancy Livada; P Daniel Ward; Leland Johnson; Alexander Mainka; Katharine J Henderson; Steffen Maune; Robert I White; Douglas A Ross
Journal:  Am J Rhinol Allergy       Date:  2012 Sep-Oct       Impact factor: 2.467

Review 8.  Hereditary haemorrhagic telangiectasia: Young's procedure in the management of epistaxis.

Authors:  A A Hosni; A J Innes
Journal:  J Laryngol Otol       Date:  1994-09       Impact factor: 1.469

Review 9.  Hereditary hemorrhagic telangiectasia: an overview of diagnosis and management in the molecular era for clinicians.

Authors:  Pinar Bayrak-Toydemir; Rong Mao; Susan Lewin; Jamie McDonald
Journal:  Genet Med       Date:  2004 Jul-Aug       Impact factor: 8.822

10.  Management of severe epistaxis after Young's procedure: a case report.

Authors:  Jonathan Y Ting; Aaron Remenschneider; Eric H Holbrook
Journal:  Int Forum Allergy Rhinol       Date:  2012-10-25       Impact factor: 3.858

View more
  1 in total

1.  The effects of nasal closure on quality of life in patients with hereditary hemorrhagic telangiectasia.

Authors:  Rhett S Thomson; Nicole L Molin; Kevin J Whitehead; Shaelene Ashby; Leland Johnson; P Daniel Ward; Bryan R McRae; Kevin F Wilson; Jamie McDonald
Journal:  Laryngoscope Investig Otolaryngol       Date:  2018-04-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.